ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Conatus Pharmaceuticals Inc

Conatus Pharmaceuticals Inc (CNAT)

0.556
0.00
( 0.00% )
Updated: 20:00:00

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.556
Bid
0.5505
Ask
0.554
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
0.556
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
-
Financial Volume
-
VWAP
-

CNAT Latest News

No news to show yet.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 23.36
(391.79%)
21.33M
XLOXilio Therapeutics Inc
$ 1.41
(120.66%)
27.88M
CEROCERo Therapeutics Holdings Inc
$ 3.14
(92.64%)
12.26M
BDRXBiodexa Pharmaceuticals PLC
$ 1.50
(74.62%)
80.62M
KYCHKeyarch Acquisition Corporation
$ 11.87
(69.44%)
152.44k
PMECPrimech Holdings Ltd
$ 1.45
(-62.63%)
5.53M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
GMDAGamida Cell Ltd
$ 0.038
(-35.81%)
61.7M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.21975
(-32.78%)
14.06M
UGROUrban Gro Inc
$ 1.3701
(-24.51%)
441.39k
NKLANikola Corporation
$ 1.015
(11.65%)
122.88M
BDRXBiodexa Pharmaceuticals PLC
$ 1.50
(74.62%)
80.62M
MARAMarathon Digital Holdings Inc
$ 22.9979
(4.20%)
63.42M
AKANAkanda Corporation
$ 0.1748
(6.00%)
62.27M
GMDAGamida Cell Ltd
$ 0.038
(-35.81%)
61.7M

CNAT Discussion

View Posts
Holdemorfoldem Holdemorfoldem 4 years ago
My guess is merger will happen. Vote expected on May 7th ... https://www.otcmarkets.com/filing/html?id=14112909&guid=IABHUqztWEfo2yh
LOGO
May 1, 2020
URGENT – PLEASE VOTE YOUR SHARES TODAY
Dear Fellow Shareholder,
I am writing to remind you that the Special Meeting of Conatus Pharmaceuticals Inc. (“Conatus”) to approve the merger with Histogen Inc. and related matters is scheduled for May 7, 2020.
Your vote is important, regardless of the number of shares you own. Please take a moment to vote your shares via the Internet, telephone OR sign, date and return the enclosed form of proxy, at your earliest convenience. Please note that voting by telephone or on the Internet will require that you have your proxy control number available. That number is printed on the enclosed form of proxy, or in an email if you elected to receive proxy materials electronically. Voting promptly will help reduce solicitation costs and eliminate the need for follow-up phone calls or mailings.
Your Board of Directors urges you to vote “FOR” all proposals.
FAILURE TO RETURN YOUR FORM OF PROXY OR A VOTE VIA THE INTERNET OR TELEPHONE MAY RESULT IN THERE NOT BEING A QUORUM PRESENT, THUS PREVENTING THE MEETING FROM OCCURRING.
PLEASE TAKE THE TIME TO VOTE TODAY.
If you have any questions or require assistance in voting your shares, please call Conatus’ proxy solicitor, Laurel Hill Advisory Group, LLC (“Laurel Hill”), at 1-888-742-1305.
You may receive a call asking you to exercise your right to vote. Laurel Hill has been retained by Conatus to make follow-up phone calls to help secure the remaining votes needed for the Special Meeting.
Thank you for taking time to vote and for your continued interest in Conatus.
Very truly yours,

LOGO
Steven J. Mento, Ph.D.
President and Chief Executive Officer


If you need assistance in voting your shares, please call our proxy solicitor, Laurel Hill Advisory Group, at 1-888-742-1305.

👍️0
ClayTrader ClayTrader 4 years ago
* * $CNAT Video Chart 05-05-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
akamaii akamaii 4 years ago
What’s going on what’s the float
👍️0
aristotelisonassis aristotelisonassis 4 years ago
PM: $0.4190? WTF!
👍️0
aristotelisonassis aristotelisonassis 4 years ago
Long $0.52
👍️0
LexTrader LexTrader 4 years ago
1.00+
👍️0
jokerwild477 jokerwild477 4 years ago
???translate to what , I have as many brain cells as a rock,.
👍️0
LexTrader LexTrader 4 years ago
The exchange ratio used to determine the number of shares of Conatus common stock issuable to Histogen stockholders pursuant to the merger was determined using a pre-transaction valuation of $100 million for Histogen’s business, based on its latest priced investment round and clinical pipeline advancement, and $35.135 million for Conatus’ business, an approximately 155% premium to the 20-day volume weighted average closing share price of Conatus prior to the signing date on the Nasdaq Capital Marke
👍️0
jokerwild477 jokerwild477 4 years ago
????????? What size is the R/S,,,,,,,,,,,!
👍️0
420man 420man 4 years ago
Big run a comin!
👍️0
chainma1l chainma1l 4 years ago
I say 0% just because the company has absolutely nothing going for it at this point. Maintaining some sort of listing compliance is just additional unnecessary expense. They should buy a fork to stick in the company.
👍️0
Beerworld Beerworld 4 years ago
If they do it's probably a precursor to issuing more shares.
👍️0
magicmk magicmk 4 years ago
What are the chances of a RS here? Been bit before on these low prices trying to become compliant
👍️0
tmeier tmeier 4 years ago
See it's happening!!
👍️0
joelawyer joelawyer 4 years ago
That would be nice! Do you base that opinion on any actual objective facts or evidence?
👍️0
tmeier tmeier 4 years ago
It'll start to uptrend soon. Hit bottom and gonna bounce!
👍️0
joelawyer joelawyer 4 years ago
Care to explain?
👍️0
tmeier tmeier 4 years ago
Gonna blow up soon!!
👍️0
weeblewobble09 weeblewobble09 5 years ago
They still have alot of cash on hand
👍️0
ClayTrader ClayTrader 5 years ago
* * $CNAT Video Chart 09-11-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
chainma1l chainma1l 5 years ago
Why volume? Why price?
👍️0
ClayTrader ClayTrader 5 years ago
* * $CNAT Video Chart 08-30-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
ClayTrader ClayTrader 5 years ago
* * $CNAT Video Chart 07-11-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
TheFinalCD TheFinalCD 5 years ago
any news or catalyst +27% hod .469

CNAT
👍️0
aristotelisonassis aristotelisonassis 5 years ago
long
👍️0
MisterE MisterE 5 years ago
Haven’t bought in yet. Waiting to see signs of life. Bounce is coming eventually
👍️0
chainma1l chainma1l 5 years ago
Here, dead kitty kitty kitty!
👍️0
ClayTrader ClayTrader 5 years ago
* * $CNAT Video Chart 07-03-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
MisterE MisterE 5 years ago
bounce coming
👍️0
willlbone willlbone 5 years ago
CNAT smashed like GNAT.
👍️0
JOHNNY-VEGAS JOHNNY-VEGAS 5 years ago
the last nail in the coffin of this dog.
👍️0
DewDiligence DewDiligence 5 years ago
Disaster strikes: #msg-149568025.
👍️0
StockNet StockNet 5 years ago
Lol
👍️0
Giovanni Giovanni 5 years ago
Thank you kiss of death
👍️0
Zmill Zmill 5 years ago
Research on CNAT and their ability to scale the Nash opportunity https://msmoneymoves.com/2019/05/22/a-high-risk-high-reward-biotech-stock-targeting-nash-cirrhosis/
👍️0
StockNet StockNet 5 years ago
Slow creep upwards...
👍️0
whytestocks whytestocks 5 years ago
News: $CNAT Conatus Pharmaceuticals Announces Publication Demonstrating that Emricasan Ameliorates Portal Hypertension, Improves Liver Structure and Function in a Preclinical Model of Advanced Cirrhosis

SAN DIEGO, April 30, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced a new publication 1 in Hepatology Communications detailing results following seven-day treatment with emricasan, the company’s first-in-class pan-caspase inhibitor, in rats...

Find out more https://marketwirenews.com/news-releases/conatus-pharmaceuticals-announces-publication-demonstrating-that-emricasan-ameliorates-portal-hypertension-improves-liver-structure-and-function-in-a-preclinical-model-of-advanced-cirrhosis-8082678.html
👍️0
BottomBounce BottomBounce 5 years ago
$CNAT $.25 coming Fiscal Year Ends Dec 30, 2018
Most Recent Quarter (mrq) Dec 30, 2018
Profitability
Profit Margin -53.62%
Operating Margin (ttm) -54.42%
Management Effectiveness
Return on Assets (ttm) -17.47%
Return on Equity (ttm) -65.02%
👍️0
ClayTrader ClayTrader 5 years ago
* * $CNAT Video Chart 04-18-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
lorema lorema 5 years ago
Look at the link, best of EASL 2019, what company is chosen

https://ilc-congress.eu/wp-content/uploads/2019/04/Best-of-ILC2019_Cirrhosis-and-complications-v1.0-190413.pptx

👍️0
Giovanni Giovanni 5 years ago
Why?

Thumbs up ?

you sure?
=========
The scientific community it’s giving a thumbs up! Any small improvement is a progress
👍️0
lorema lorema 5 years ago
Out of hundreds of companies presenting and 2800 poster presentations, Emricasan emerged as one of the best developments in EASL.

This should’ve gone up not down.


https://ilc-congress.eu/wp-content/uploads/2019/04/Best-of-ILC2019_Cirrhosis-and-complications-v1.0-190413.pptx
👍️0
fishhunter fishhunter 5 years ago
If you look at all the summary slides even where change was not significant it was still in the right direction and meaningful. The drug works and is worth something.
👍️0
lorema lorema 5 years ago
From EASL 2019
https://ilc-congress.eu/congress-news/ilc-daily-news-saturday-recap/
“In the ENCORE-PH Phase 2b trial in patients with NASH-related compensated cirrhosis with severe portal hypertension, treatment with oral pan-caspase inhibitor emricasan showed a trend toward greater change from baseline in hepatic venous pressure gradient (HPVG: primary endpoint) and clinically meaningful HPVG reduction in patients with very high baseline HPVG (≥16 mmHg).”
👍️0
ClayTrader ClayTrader 5 years ago
* * $CNAT Video Chart 04-15-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
Castisos0 Castisos0 5 years ago
I dunno but market over reacted to this for sure
👍️0
lorema lorema 5 years ago
In 2016, few months after Tobira failed to meet the primary endpoint for its NASH trial, was purchased for 1.7 billion by Allergan. Just because they miss the primary endpoint doesn’t mean that it is a complete failure. They look for other parameters.
👍️0
lorema lorema 5 years ago
The fact that it was accepted as a late breaking oral presentation was worthy of PR. Also, of importance was the fact that it was selected by EASL for inclusion in the “Best of ILC” summary slide deck highlighting the most noteworthy contributions to the scientific program at this year’s meeting. But what do they know?

👍️0
fishhunter fishhunter 5 years ago
It was previously announced Dec 5, 2018. The headlines and stuff today were the very definition of FAKE NEWS. All the Saturday presentation had was a bit more depth to the data but all the big conclusions were the same as on Dec 5th. Crazy
👍️0
weeblewobble09 weeblewobble09 5 years ago
Its four month old data. They missed the endpoint four months ago.
Waiting for 48 week data still.
👍️0

Your Recent History

Delayed Upgrade Clock